Intellectual Property Portfolio

Strategic patent protection for our diagnostic platform and precision serology markers. Our IP position reflects years of discovery, validation, and commercialization expertise in epitope-level diagnostics.

Gastric Cancer Risk

Helitope identifies individuals infected with oncogenic H. pylori strains carrying specific CagA variants, distinguishing the ~3% of patients at elevated gastric cancer risk from those with benign infections.

Granted Patents - 20+ jurisdictions

WO2018153991 - Novel peptides and their use in diagnosis
US 11,401,308 (granted 2022)
Granted in: Australia, Europe, Japan, China, South Korea, Singapore, Spain, Sweden

Continuation Application

AU2024219396A1 - Novel peptides and their use in diagnosis

Unlike conventional H. pylori tests that simply detect infection, our markers stratify cancer risk by identifying antibody responses to specific virulence factor epitopes. This comprehensive patent coverage creates significant barriers to entry and provides strong positioning for licensing partnerships in Asia-Pacific regions where gastric cancer burden is highest.

More about Helitope, our stomach cancer risk assay

Preeclampsia Risk Assessment

PreACT uses autoantibody profiling to identify pregnant women at elevated preeclampsia risk. Early identification enables aspirin intervention before 16 weeks gestation, significantly reducing preeclampsia incidence and associated complications.

International Application

WO2025000054A1 - Helicobacter CagA peptides and their use in diagnosis
Covers use of CagA-derived peptides for prevention and prognosis of vascular and epithelial pathologies including preeclampsia

Australian Provisional Patents

AU2023902109A0 - Predicting preeclampsia in pregnant women
AU2023902106A0 - Peptides and their use in diagnosis
AU2023902104A0 - Peptides and their use in diagnosis

Our epitope mapping identified novel autoantibody targets with strong diagnostic performance. The peptide-based format enables cost-effective manufacture at scale, multiplexing capability, and precise targeting of disease-specific epitopes.

More about Preact, our preeclampsia risk assay

SARS-CoV-2 Serology

Covitope demonstrated rapid platform adaptability during pandemic response. Linear epitope mapping across the SARS-CoV-2 proteome identified peptides with minimal cross-reactivity to endemic coronaviruses while maintaining sensitivity across viral strains.

International Application

EP4298113A4 - Peptides and their use in diagnosis of SARS-CoV-2 infection
Jurisdictions: WO, EP, US, AU, CA

Australian Provisional Patents

AU2021900506A0 - Peptides and their use in diagnosis of SARS-CoV-2 infection
AU2020900887A0 - Peptides and their use in diagnosis
AU2020900885A0 - Peptides and their use in diagnosis

This validated IP package suits licensing to diagnostic manufacturers or integration into multiplexed respiratory panels, particularly valuable for companies building comprehensive infectious disease portfolios.

Platform Technology

Peptide Augmentation Method

AU 2025902422 (Provisional) - Peptide modification technology for enhanced sensitivity

Peptide modifications that increases diagnostic sensitivity without traditional conjugation chemistry.

Fundamental to all our diagnostic programs.

Additional Applications

AU2022900537A0 - Peptides and their use in diagnosis
AU2022900536A0 - Peptides and their use in diagnosis
AU2021900617A0 - Peptides and their use in diagnosis
AU2021900616A0 - Peptides and their use in diagnosis

Partnership Opportunities

We're actively seeking partners for licensing our diagnostic IP, technology platform, or specific market territories. Our patent portfolio provides strong freedom-to-operate and commercial protection for precision serology applications.

Whether you're developing diagnostics, building an IP portfolio in infectious disease or women's health, or seeking proven peptide-ELISA technology, our protected innovations offer validated pathways to market.

Contact: info@biotome.com.au